Literature DB >> 27863129

Mechanisms of obesity in Prader-Willi syndrome.

M J Khan1,2, K Gerasimidis2, C A Edwards2, M G Shaikh3.   

Abstract

Obesity is the most common cause of metabolic complications and poor quality of life in Prader-Willi syndrome (PWS). Hyperphagia and obesity develop after an initial phase of poor feeding and failure to thrive. Several mechanisms for the aetiology of obesity in PWS are proposed, which include disruption in hypothalamic pathways of satiety control resulting in hyperphagia, aberration in hormones regulating food intake, reduced energy expenditure because of hypotonia and altered behaviour with features of autism spectrum disorder. Profound muscular hypotonia prevents PWS patients from becoming physically active, causing reduced muscle movements and hence reduced energy expenditure. In a quest for the aetiology of obesity, recent evidence has focused on several appetite-regulating hormones, growth hormone, thyroid hormones and plasma adipocytokines. However, despite advancement in understanding of the genetic basis of PWS, there are contradictory data on the role of satiety hormones in hyperphagia and data regarding dietary intake are limited. Mechanistic studies on the aetiology of obesity and its relationship with disease pathogenesis in PWS are required. . In this review, we focused on the available evidence regarding mechanisms of obesity and potential new areas that could be explored to help unravel obesity pathogenesis in PWS.
© 2016 World Obesity Federation.

Entities:  

Keywords:  Prader-Willi syndrome; body composition; hypothalamic satiety regulation; obesity

Mesh:

Year:  2016        PMID: 27863129     DOI: 10.1111/ijpo.12177

Source DB:  PubMed          Journal:  Pediatr Obes        ISSN: 2047-6302            Impact factor:   4.000


  18 in total

Review 1.  Genetic and Syndromic Causes of Obesity and its Management.

Authors:  Ildiko H Koves; Christian Roth
Journal:  Indian J Pediatr       Date:  2017-11-27       Impact factor: 1.967

Review 2.  Epigenetic therapy of Prader-Willi syndrome.

Authors:  Yuna Kim; Sung Eun Wang; Yong-Hui Jiang
Journal:  Transl Res       Date:  2019-03-05       Impact factor: 7.012

Review 3.  Biological, Behavioral, and Ethical Considerations of Prader-Willi Syndrome: A Primer for Behavior Analysts.

Authors:  Danielle Kennedy; Halle Marten; Clare O'Sullivan; Rocco Catrone
Journal:  Behav Anal Pract       Date:  2021-07-08

4.  Patients with Prader-Willi Syndrome (PWS) Underwent Bariatric Surgery Benefit more from High-Intensity Home Care.

Authors:  Songhao Hu; Biao Huang; Ken Loi; Xiaomei Chen; Qinyu Ding; Lan Luo; Cunchuan Wang; Wah Yang
Journal:  Obes Surg       Date:  2022-03-15       Impact factor: 3.479

5.  Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader-Willi Syndrome.

Authors:  Agnieszka Lecka-Ambroziak; Marta Wysocka-Mincewicz; Katarzyna Doleżal-Ołtarzewska; Agata Zygmunt-Górska; Teresa Żak; Anna Noczyńska; Dorota Birkholz-Walerzak; Renata Stawerska; Maciej Hilczer; Monika Obara-Moszyńska; Barbara Rabska-Pietrzak; Elżbieta Gołębiowska; Adam Dudek; Elżbieta Petriczko; Mieczysław Szalecki
Journal:  Diagnostics (Basel)       Date:  2021-04-28

6.  MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus.

Authors:  Patricia Blanchet; Martina Bebin; Shaam Bruet; Gregory M Cooper; Michelle L Thompson; Benedicte Duban-Bedu; Benedicte Gerard; Amelie Piton; Sylvie Suckno; Charu Deshpande; Virginia Clowes; Julie Vogt; Peter Turnpenny; Michael P Williamson; Yves Alembik; Eric Glasgow; Alisdair McNeill
Journal:  PLoS Genet       Date:  2017-08-31       Impact factor: 5.917

Review 7.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

8.  Body composition, adipokines, bone mineral density and bone remodeling markers in relation to IGF-1 levels in adults with Prader-Willi syndrome.

Authors:  I Caroline van Nieuwpoort; Jos W R Twisk; Leopold M G Curfs; Paul Lips; Madeleine L Drent
Journal:  Int J Pediatr Endocrinol       Date:  2018-01-16

9.  Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: a single center experience.

Authors:  Aram Yang; Jinsup Kim; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Orphanet J Rare Dis       Date:  2017-08-30       Impact factor: 4.123

10.  Caralluma fimbriata extract activity involves the 5-HT2c receptor in PWS Snord116 deletion mouse model.

Authors:  Joanne L Griggs; Michael L Mathai; Puspha Sinnayah
Journal:  Brain Behav       Date:  2018-10-23       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.